구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | CAR-T cells chimeric antigen receptor T cells (CAR-T cells chimeric antigen receptor T cells) CARsgen Therapeutics Co., Ltd.·FRα 33 trials |
|---|---|
Overview Program | CAR-T cells chimeric antigen receptor T cells |
Overview Company | CARsgen Therapeutics Co., Ltd. |
Overview Modality | CGT |
Overview Target | FRα |
Overview Indication | AML; Refractory/Relapse Acute Myeloid Leukemia |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Vector | lentiviral expression vector and removed epitope tags used to discriminate between CAR and |
MoA Mechanism | targeting B cell maturation antigen |
MoA Biomarker | biomarker-driven methods were among the clinically orientated themes that emerged from foundational and precl |
PK/PD Species | Mouse, no neurotoxicity was observed. |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, no neurotoxicity was observed. |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events.. Immunotherapies targeting B cell maturation antigen (BCMA) in multiple myeloma are transitioning through trials and entering the clinic, and will likely become a core pillar in myeloma therapeutics. These agents demonstrate unprecedented activity in multiply relapsed patients, but notwithsta… |
Toxicology CRS | Reported |
Clinical Safety signal | BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events.. Immunotherapies targeting B cell maturation antigen (BCMA) in multiple myeloma are transitioning through trials and entering the clinic, and will likely become a core pillar in myeloma therapeutics. These agents demonstrate unprecedented activity in multiply relapsed patients, but notwithsta… |
Clinical Reported ORR | 0% |
Clinical Reported PFS | 0.99 |
Clinical Reported OS | 4.50 |
Clinical Result source | ClinicalTrials.gov NCT05714345 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT05714345 |
Preclinical Animal (cat.) | Mouse, In vitro |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | CAR-T cells chimeric antigen receptor T cells (CAR-T cells chimeric antigen receptor T cells) CARsgen Therapeutics Co., Ltd.·FRα 33 trials |
|---|---|
Overview Program | CAR-T cells chimeric antigen receptor T cells |
Overview Company | CARsgen Therapeutics Co., Ltd. |
Overview Modality | CGT |
Overview Target | FRα |
Overview Indication | AML; Refractory/Relapse Acute Myeloid Leukemia |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Vector | lentiviral expression vector and removed epitope tags used to discriminate between CAR and |
MoA Mechanism | targeting B cell maturation antigen |
MoA Biomarker | biomarker-driven methods were among the clinically orientated themes that emerged from foundational and precl |
PK/PD Species | Mouse, no neurotoxicity was observed. |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, no neurotoxicity was observed. |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events.. Immunotherapies targeting B cell maturation antigen (BCMA) in multiple myeloma are transitioning through trials and entering the clinic, and will likely become a core pillar in myeloma therapeutics. These agents demonstrate unprecedented activity in multiply relapsed patients, but notwithsta… |
Toxicology CRS | Reported |
Clinical Safety signal | BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events.. Immunotherapies targeting B cell maturation antigen (BCMA) in multiple myeloma are transitioning through trials and entering the clinic, and will likely become a core pillar in myeloma therapeutics. These agents demonstrate unprecedented activity in multiply relapsed patients, but notwithsta… |
Clinical Reported ORR | 0% |
Clinical Reported PFS | 0.99 |
Clinical Reported OS | 4.50 |
Clinical Result source | ClinicalTrials.gov NCT05714345 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT05714345 |
Preclinical Animal (cat.) | Mouse, In vitro |
추천 비교
추천 비교